FENC Fennec Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FENC

Price (delayed)

$9.23

Market cap

$250.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$266.6M

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation ...

Highlights
FENC's revenue has soared by 63% from the previous quarter
The gross profit has soared by 61% from the previous quarter
The quick ratio has contracted by 47% YoY and by 33% from the previous quarter
FENC's debt is up by 21% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://fennecpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FENC
Market
Shares outstanding
27.1M
Market cap
$250.13M
Enterprise value
$266.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.54
Earnings
Revenue
$21.25M
EBIT
-$12.65M
EBITDA
-$12.65M
Free cash flow
-$17.14M
Per share
EPS
-$0.6
Free cash flow per share
-$0.65
Book value per share
-$0.44
Revenue per share
$0.8
TBVPS
$1.01
Balance sheet
Total assets
$26.86M
Total liabilities
$38.49M
Debt
$29.74M
Equity
-$11.62M
Working capital
$19.31M
Liquidity
Debt to equity
-2.56
Current ratio
3.56
Quick ratio
2.92
Net debt/EBITDA
-1.3
Margins
EBITDA margin
-59.5%
Gross margin
94.1%
Net margin
-75.5%
Operating margin
-60.1%
Efficiency
Return on assets
-73.6%
Return on equity
N/A
Return on invested capital
-44.9%
Return on capital employed
-65.5%
Return on sales
-59.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FENC stock price

How has the Fennec Pharmaceuticals stock price performed over time
Intraday
1.54%
1 week
0.22%
1 month
-14.3%
1 year
11.95%
YTD
-17.74%
QTD
-17%

Financial performance

How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$21.25M
Gross profit
$19.99M
Operating income
-$12.77M
Net income
-$16.05M
Gross margin
94.1%
Net margin
-75.5%
Fennec Pharmaceuticals's operating margin has soared by 96% YoY and by 54% from the previous quarter
FENC's net margin has surged by 95% year-on-year and by 51% since the previous quarter
FENC's revenue has soared by 63% from the previous quarter
The gross profit has soared by 61% from the previous quarter

Growth

What is Fennec Pharmaceuticals's growth rate over time

Valuation

What is Fennec Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
11.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.54
The company's EPS rose by 33% YoY and by 21% QoQ
The equity has contracted by 10% from the previous quarter
The P/S is 66% lower than the last 4 quarters average of 33.5
FENC's revenue has soared by 63% from the previous quarter

Efficiency

How efficient is Fennec Pharmaceuticals business performance
The company's return on sales has surged by 96% YoY and by 54% QoQ
The return on invested capital has surged by 74% year-on-year and by 34% since the previous quarter
The return on assets has increased by 29% year-on-year and by 21% since the previous quarter

Dividends

What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FENC.

Financial health

How did Fennec Pharmaceuticals financials performed over time
The total assets is 30% less than the total liabilities
The quick ratio has contracted by 47% YoY and by 33% from the previous quarter
The total assets has grown by 41% from the previous quarter
The company's debt to equity has surged by 73% YoY but it fell by 9% QoQ
FENC's debt is up by 21% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.